Form 4: Marimed CCO Ryan Crandall Converts RSUs, Adjusts Holdings

Marimed Inc.'s Chief Commercial Officer, Ryan Crandall, converted 75,000 Restricted Stock Units into common stock and sold shares to cover tax obligations.

Summary

• Ryan Crandall, Chief Commercial Officer of Marimed Inc. (MRMD), converted 75,000 Restricted Stock Units (RSUs) into common stock on November 29, 2025.
• These RSUs converted on a one-for-one basis, resulting in the acquisition of 75,000 shares of common stock at an exercise price of $0.
• Concurrently, 22,013 shares of common stock were disposed of at a price of $0.0896 to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Crandall beneficially owns 784,925 shares of Marimed Inc. common stock directly.
• An additional 150,000 RSUs remain outstanding, granted on November 29, 2024, with future vesting scheduled in four equal installments through November 29, 2027.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the vesting of Restricted Stock Units and subsequent share disposal for tax purposes. This is a neutral event, neither inherently positive nor negative for the company's operational or financial performance, but rather a standard compensation mechanism.

Positives

• Conversion of Restricted Stock Units indicates a portion of executive compensation is being realized, aligning management interests with shareholders.
• The executive continues to hold a significant number of shares (784,925) and unvested RSUs (150,000), demonstrating continued stake in the company's performance.

Negatives

• A portion of shares (22,013) were sold to cover tax obligations, which is a common practice but represents a reduction in direct ownership.

Future Outlook

The remaining 150,000 Restricted Stock Units (RSUs) are scheduled to vest in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027, and November 29, 2027, in accordance with the award agreement.

Industry Context

This is a routine insider transaction related to executive compensation and vesting of equity awards. It does not inherently reflect broader industry trends or competitive positioning, but rather the standard compensation practices within publicly traded companies, including those in the cannabis or related sectors where Marimed operates.

Comparison to Industry Standards

• This filing details a standard RSU vesting and tax withholding event, which is a common practice for executive compensation across various industries. There are no specific comparable companies, projects, or results mentioned in this transactional filing to assess against global benchmarks.

Stakeholder Impact

• Shareholders: The transaction reflects a routine compensation event for a key executive. The sale of shares for tax purposes slightly increases the float but is a common practice. The executive's continued significant holding of shares and RSUs aligns their interests with long-term shareholder value.
• Employees: This demonstrates the company's equity compensation structure for executives, which can influence broader employee compensation strategies and morale.

Next Steps

• Future vesting of the remaining 150,000 Restricted Stock Units in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027, and November 29, 2027.

Key Dates

Keywords

Marimed Inc., MRMD, Ryan Crandall, Chief Commercial Officer, CCO, SEC Form 4, Insider Trading, Restricted Stock Units, RSU conversion, Stock vesting, Tax withholding, Beneficial ownership